DiaMedica Therapeutics (DMAC) Competitors $4.13 -0.02 (-0.48%) Closing price 04:00 PM EasternExtended Trading$4.16 +0.03 (+0.73%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. DAWN, OCS, CVAC, ABCL, RCKT, QURE, XNCR, LENZ, PAHC, and IMNMShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Day One Biopharmaceuticals (DAWN), Oculis (OCS), CureVac (CVAC), AbCellera Biologics (ABCL), Rocket Pharmaceuticals (RCKT), uniQure (QURE), Xencor (XNCR), LENZ Therapeutics (LENZ), Phibro Animal Health (PAHC), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Day One Biopharmaceuticals Oculis CureVac AbCellera Biologics Rocket Pharmaceuticals uniQure Xencor LENZ Therapeutics Phibro Animal Health Immunome DiaMedica Therapeutics (NASDAQ:DMAC) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Which has more volatility and risk, DMAC or DAWN? DiaMedica Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.24, suggesting that its stock price is 224% less volatile than the S&P 500. Does the media favor DMAC or DAWN? In the previous week, Day One Biopharmaceuticals had 7 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 9 mentions for Day One Biopharmaceuticals and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.97 beat Day One Biopharmaceuticals' score of 0.52 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Day One Biopharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer DMAC or DAWN? DiaMedica Therapeutics received 40 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. However, 70.13% of users gave Day One Biopharmaceuticals an outperform vote while only 63.09% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformDiaMedica TherapeuticsOutperform Votes9463.09% Underperform Votes5536.91% Day One BiopharmaceuticalsOutperform Votes5470.13% Underperform Votes2329.87% Do institutionals and insiders believe in DMAC or DAWN? 10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Day One Biopharmaceuticals shares are held by institutional investors. 7.3% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is DMAC or DAWN more profitable? Day One Biopharmaceuticals' return on equity of -22.40% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets DiaMedica TherapeuticsN/A -43.67% -40.81% Day One Biopharmaceuticals N/A -22.40%-19.79% Do analysts rate DMAC or DAWN? DiaMedica Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 92.03%. Day One Biopharmaceuticals has a consensus price target of $32.29, indicating a potential upside of 322.92%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Day One Biopharmaceuticals is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has higher valuation and earnings, DMAC or DAWN? DiaMedica Therapeutics has higher earnings, but lower revenue than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaMedica TherapeuticsN/AN/A-$19.38M-$0.60-6.94Day One Biopharmaceuticals$131.16M5.90-$188.92M-$1.08-7.07 SummaryDay One Biopharmaceuticals beats DiaMedica Therapeutics on 11 of the 17 factors compared between the two stocks. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$177.85M$6.72B$5.49B$7.94BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-7.417.3722.5818.55Price / SalesN/A242.94397.25103.00Price / CashN/A65.8538.1834.62Price / Book3.096.486.704.26Net Income-$19.38M$143.68M$3.23B$248.39M7 Day Performance-0.10%1.79%1.26%1.27%1 Month Performance11.09%6.68%3.75%3.85%1 Year Performance60.85%-2.73%15.78%5.23% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics1.7038 of 5 stars$4.13-0.5%$8.00+93.7%+60.9%$177.00MN/A-7.3720Upcoming EarningsDAWNDay One Biopharmaceuticals2.4717 of 5 stars$7.74flat$32.29+317.1%-54.5%$784.48M$131.16M-7.5160Upcoming EarningsNews CoverageOCSOculis2.8677 of 5 stars$17.86+5.1%$30.25+69.4%+33.1%$779.80M$980,000.00-9.252Short Interest ↓News CoverageCVACCureVac3.9574 of 5 stars$3.47+7.4%$16.00+361.1%+40.9%$778.45M$535.18M6.31880Analyst ForecastABCLAbCellera Biologics2.5964 of 5 stars$2.59+0.8%$7.50+189.6%-31.0%$771.79M$28.83M-4.25500Upcoming EarningsPositive NewsRCKTRocket Pharmaceuticals4.6769 of 5 stars$7.16-1.0%$43.00+500.6%-64.5%$763.47MN/A-2.60240Upcoming EarningsQUREuniQure2.573 of 5 stars$13.97-1.5%$38.80+177.7%+234.7%$755.46M$27.12M-2.82500Upcoming EarningsShort Interest ↑Analyst RevisionXNCRXencor3.5183 of 5 stars$10.60+0.9%$33.86+219.4%-47.4%$754.21M$110.49M-3.31280Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsLENZLENZ Therapeutics1.9488 of 5 stars$27.28+1.5%$46.60+70.8%+79.6%$751.37MN/A-5.72110Upcoming EarningsPositive NewsPAHCPhibro Animal Health3.3373 of 5 stars$18.43+2.4%$19.75+7.2%+11.4%$746.47M$1.11B38.401,860Upcoming EarningsPositive NewsIMNMImmunome2.6109 of 5 stars$8.58+2.1%$25.14+193.0%-37.5%$746.04M$9.04M-1.0640Positive News Related Companies and Tools Related Companies Day One Biopharmaceuticals Alternatives Oculis Alternatives CureVac Alternatives AbCellera Biologics Alternatives Rocket Pharmaceuticals Alternatives uniQure Alternatives Xencor Alternatives LENZ Therapeutics Alternatives Phibro Animal Health Alternatives Immunome Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DMAC Stock Free DMAC Stock Alerts